Tags

Type your tag names separated by a space and hit enter

Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study.
Bone. 2011 Mar 01; 48(3):451-5.BONE

Abstract

INTRODUCTION

In animal model, mice treated with beta-blockers (BB) had increased bone mass. In humans, high bone mass is associated with reduce fracture risk. The present study sought to test the hypothesis that BB use is associated with reduced fracture risk.

MATERIALS AND METHODS

Data from 3488 participants (1285 men) aged 50 years and above in the Dubbo Osteoporosis Epidemiology Study (DOES) were analyzed. Baseline characteristics of participants were obtained at the initial visit which had taken place between 1989 and 1993. Bone mineral density (BMD) at the lumbar spine and femoral neck was measured by dual energy X-ray absorptiometry (GE-LUNAR Corp, Madison, WI). Two hundred and sixty two (20%) men and 411 (19%) women had been on BB, as ascertained by direct interview and verification with medication history. The incidence of fragility fractures was ascertained during the follow-up period (1989-2008).

RESULTS

In men, BB use was associated with higher BMD at the femoral neck (0.96 versus 0.92 g/cm², P < 0.01), higher lumbar spine (1.32 versus 1.25 g/cm², P < 0.01), and lower fracture risk than those not on BB (odds ratio [OR]: 0.49; 95% CI: 0.32-0.75). In women, BB users also had higher femoral neck BMD (0.83 versus 0.81 g/cm², P < 0.01), higher lumbar spine BMD (1.11 versus 1.06 g/cm², P < 0.01), and lower risk of fracture than non-users (OR 0.68, 95% CI: 0.53-0.87). The associations between BB use and fracture risk were independent of age, BMD, and clinical risk factors. Subgroup analysis suggested that the association was mainly found in selective BB, not in non-selective BB.

CONCLUSION

Beta-blockers use, particularly selective BB, was associated with reduced fracture risk in both men and women, and the association was independent of BMD.

Authors+Show Affiliations

Osteoporosis and Bone Biology Research, Garvan Institute of Medical Research, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21047567

Citation

Yang, Shuman, et al. "Association Between Beta-blocker Use and Fracture Risk: the Dubbo Osteoporosis Epidemiology Study." Bone, vol. 48, no. 3, 2011, pp. 451-5.
Yang S, Nguyen ND, Center JR, et al. Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011;48(3):451-5.
Yang, S., Nguyen, N. D., Center, J. R., Eisman, J. A., & Nguyen, T. V. (2011). Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone, 48(3), 451-5. https://doi.org/10.1016/j.bone.2010.10.170
Yang S, et al. Association Between Beta-blocker Use and Fracture Risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011 Mar 1;48(3):451-5. PubMed PMID: 21047567.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association between beta-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. AU - Yang,Shuman, AU - Nguyen,Nguyen D, AU - Center,Jacqueline R, AU - Eisman,John A, AU - Nguyen,Tuan V, Y1 - 2010/11/01/ PY - 2010/07/06/received PY - 2010/10/01/revised PY - 2010/10/18/accepted PY - 2010/11/5/entrez PY - 2010/11/5/pubmed PY - 2011/5/24/medline SP - 451 EP - 5 JF - Bone JO - Bone VL - 48 IS - 3 N2 - INTRODUCTION: In animal model, mice treated with beta-blockers (BB) had increased bone mass. In humans, high bone mass is associated with reduce fracture risk. The present study sought to test the hypothesis that BB use is associated with reduced fracture risk. MATERIALS AND METHODS: Data from 3488 participants (1285 men) aged 50 years and above in the Dubbo Osteoporosis Epidemiology Study (DOES) were analyzed. Baseline characteristics of participants were obtained at the initial visit which had taken place between 1989 and 1993. Bone mineral density (BMD) at the lumbar spine and femoral neck was measured by dual energy X-ray absorptiometry (GE-LUNAR Corp, Madison, WI). Two hundred and sixty two (20%) men and 411 (19%) women had been on BB, as ascertained by direct interview and verification with medication history. The incidence of fragility fractures was ascertained during the follow-up period (1989-2008). RESULTS: In men, BB use was associated with higher BMD at the femoral neck (0.96 versus 0.92 g/cm², P < 0.01), higher lumbar spine (1.32 versus 1.25 g/cm², P < 0.01), and lower fracture risk than those not on BB (odds ratio [OR]: 0.49; 95% CI: 0.32-0.75). In women, BB users also had higher femoral neck BMD (0.83 versus 0.81 g/cm², P < 0.01), higher lumbar spine BMD (1.11 versus 1.06 g/cm², P < 0.01), and lower risk of fracture than non-users (OR 0.68, 95% CI: 0.53-0.87). The associations between BB use and fracture risk were independent of age, BMD, and clinical risk factors. Subgroup analysis suggested that the association was mainly found in selective BB, not in non-selective BB. CONCLUSION: Beta-blockers use, particularly selective BB, was associated with reduced fracture risk in both men and women, and the association was independent of BMD. SN - 1873-2763 UR - https://www.unboundmedicine.com/medline/citation/21047567/Association_between_beta_blocker_use_and_fracture_risk:_the_Dubbo_Osteoporosis_Epidemiology_Study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S8756-3282(10)01988-5 DB - PRIME DP - Unbound Medicine ER -